or Try an Advanced Search...

    Technical Analysis for OLMA - Olema Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    F 9.90 -7.56% -0.81
    OLMA closed down 7.56 percent on Thursday, April 18, 2024, on approximately normal volume.
    Earnings due: May 7
    *** please verify all earnings dates ***
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical OLMA trend table...
    Date Alert Name Type % Chg
    Bollinger Band Squeeze Range Contraction 0.00%
    Multiple of Ten Bearish Other 0.00%
    BB Squeeze + Lower Band Touch Range Contraction 0.00%
    Below Lower BB Weakness 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Down 5 Days in a Row Weakness 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Bollinger Band Squeeze Range Contraction -7.56%
    Down 3 Days in a Row Weakness -7.56%
    Older End-of-Day Signals for OLMA ...

       Recent Intraday Alerts

    Alert Time
    Down 1 ATR about 21 hours ago
    Down 5% about 22 hours ago
    60 Minute Opening Range Breakdown about 22 hours ago
    Down 3% about 23 hours ago
    Fell Below Lower Bollinger Band about 23 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    OLMA Chart by TradingView
    Basic chart:

    Profile

    Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Olema is headquartered in San Francisco.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Clinical Medicine Breast Cancer Treatment Of Breast Cancer Epidermal Growth Factor Receptor Hormones Targeted Therapy Her2 Her2/Neu Estrogen Antiestrogens Estrogen Receptor Selective Estrogen Receptor Degraders Fulvestrant

    Is OLMA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 8 Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
    Apr 5 Goldman Sachs Predicts Over 120% Rally for These 2 ‘Strong Buy’ Stocks
    Mar 28 Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path
    Mar 11 Olema Pharmaceuticals GAAP EPS of -$0.49
    Mar 11 Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
    Mar 6 Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
    Mar 4 Calculating The Intrinsic Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
    Feb 2 Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Jan 31 Olema Pharmaceuticals files to sell 13.21M common shares for holders
    Jan 22 15 Small-Cap Stocks with High Potential
    See more OLMA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 17.7911
    52 Week Low 3.86
    Average Volume 823,570
    200-Day Moving Average 12.10
    50-Day Moving Average 12.60
    20-Day Moving Average 10.98
    10-Day Moving Average 10.91
    Average True Range 0.77
    RSI (14) 35.06
    ADX 29.66
    +DI 9.91
    -DI 24.28
    Chandelier Exit (Long, 3 ATRs) 9.54
    Chandelier Exit (Short, 3 ATRs) 12.09
    Upper Bollinger Bands 11.74
    Lower Bollinger Band 10.22
    Percent B (%b) -0.21
    BandWidth 13.86
    MACD Line -0.48
    MACD Signal Line -0.49
    MACD Histogram 0.0041
    Fundamentals Value
    Market Cap 545.46 Million
    Num Shares 55.1 Million
    EPS -2.31
    Price-to-Earnings (P/E) Ratio -4.29
    Price-to-Sales 0.00
    Price-to-Book 3.05
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 11.37
    Resistance 3 (R3) 11.49 11.12 11.12
    Resistance 2 (R2) 11.12 10.75 11.06 11.04
    Resistance 1 (R1) 10.51 10.52 10.33 10.39 10.96
    Pivot Point 10.15 10.15 10.06 10.09 10.15
    Support 1 (S1) 9.54 9.77 9.35 9.41 8.84
    Support 2 (S2) 9.17 9.54 9.11 8.76
    Support 3 (S3) 8.56 9.17 8.68
    Support 4 (S4) 8.43